1. Home
  2. FBGL vs APRE Comparison

FBGL vs APRE Comparison

Compare FBGL & APRE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

FBGL

FBS Global Limited Ordinary Shares

HOLD

Current Price

$0.58

Market Cap

11.3M

ML Signal

HOLD

Logo Aprea Therapeutics Inc.

APRE

Aprea Therapeutics Inc.

HOLD

Current Price

$0.73

Market Cap

11.5M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
FBGL
APRE
Founded
1996
2006
Country
Singapore
United States
Employees
N/A
N/A
Industry
Miscellaneous manufacturing industries
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
11.3M
11.5M
IPO Year
N/A
2019

Fundamental Metrics

Financial Performance
Metric
FBGL
APRE
Price
$0.58
$0.73
Analyst Decision
Strong Buy
Analyst Count
0
2
Target Price
N/A
$4.10
AVG Volume (30 Days)
86.3K
180.8K
Earning Date
05-15-2026
05-13-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
21.22
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.34
$0.55
52 Week High
$1.40
$2.22

Technical Indicators

Market Signals
Indicator
FBGL
APRE
Relative Strength Index (RSI) 39.65 38.23
Support Level $0.40 $0.57
Resistance Level $0.69 $1.00
Average True Range (ATR) 0.09 0.08
MACD -0.01 -0.02
Stochastic Oscillator 25.15 10.31

Price Performance

Historical Comparison
FBGL
APRE

About FBGL FBS Global Limited Ordinary Shares

FBS Global Ltd is a green building contractor and an established interior fit-out specialist in institutional, residential, commercial, and industrial building projects. As a green contractor focused on environmentally sound practices, the company aims to bid tenders for green building projects, use green construction methods and green materials for construction projects, including design, supply and installation of ceilings, partitions, timber deck, carpet, acoustic wall paneling, built-in furniture as well as mechanical and electrical services of a building. The company's revenue is derived mainly from the construction contracts and Sales of construction materials.

About APRE Aprea Therapeutics Inc.

Aprea Therapeutics Inc is a clinical-stage precision medicine oncology company focused on the discovery and development of targeted therapies for patients with biomarker-defined cancers. It develops small molecule inhibitors designed to exploit genetic mutations in cancer to widen the therapeutic window and is intended to make treatments more effective at destroying cancer cells while sparing healthy tissue. The company's pipeline of clinical and preclinical programs includes APR-1051, a WEE1 inhibitor; ATRN-119 (Mosipasertib), an oral small molecule inhibitor of ataxia telangiectasia and Rad3-related, or ATR; and an early-stage program, APR-1602. These candidates are being developed for broad applications in cancer treatment.

Share on Social Networks: